ProPharma Group, a portfolio company of Linden Capital Partners, announces the acquisition of Xendo Holding B.V. (“Xendo”), a Netherlands-based provider of compliance consulting, engineering & technical support, regulatory affairs, and pharmacovigilance services to the (bio)pharmaceutical, medical device and healthcare industries. The acquisition of Xendo also includes Sofus Regulatory Affairs AB, based in Sweden. “We are excited to support the entire ProPharma Group organization as they continue to build out capabilities and expand their global presence to better serve their customers”, said Michael Farah, Chairman of ProPharma Group and Partner at Linden Capital Partners.
For more than 25 years, Xendo has provided (bio)pharmaceutical and medical device clients worldwide with quality management, engineering, regulatory affairs, pharmacovigilance, and product development services, having successfully completed thousands of assignments. This acquisition expands ProPharma Group’s geographic coverage for compliance consulting services to include Europe and adds additional high-value regulatory affairs and pharmacovigilance services making ProPharma Group a single-source, global independent provider of compliance, regulatory affairs, pharmacovigilance, and medical information solutions. “We are thrilled about our future as part of ProPharma Group. The combination expands our global reach and service offering to our clients”, said André van de Sande, Xendo’s CEO.
ProPharma Group continues to build a global presence in size and scale as the company will now have over 1,000 employees across United States, Europe, Japan, and Australia. Xendo’s professionals and their knowledge-driven approach will perfectly align with ProPharma Group’s services worldwide. Xendo’s leadership team brings an abundance of industry knowledge and expertise that will complement ProPharma Group’s leadership team. “Combining the collective expertise of both organizations creates a unique, independent, and fully integrated compliance offering that will provide our clients with expanded services and true global reach”, said Dawn Sherman, President & CEO, ProPharma Group.
About ProPharma Group
ProPharma Group, a portfolio company of Linden Capital Partners, is a global industry leader in comprehensive compliance services that span the entire lifecycle of pharmaceuticals, biologics, and devices. ProPharma Group has more than 1,000 colleagues worldwide providing an unmatched variety of compliance related services including medical information, pharmacovigilance, clinical safety, regulatory affairs, and a continuously expanding range of compliance, quality assurance, validation, and consulting services.
About Linden Capital Partners
Linden Capital Partners is a Chicago-based private equity firm focused exclusively on leveraged buyouts in the healthcare industry. Linden’s strategy is based upon three elements: i) healthcare specialization, ii) integrated private equity and operating expertise, and iii) strategic relationships with large corporations. Linden invests in middle market platforms in the medical products, specialty distribution, pharmaceutical, and services segments of healthcare.
Your Business has Complex Challenges. ProPharma Group has Exceptional Solutions.
We partner with pharmaceutical, biotechnology, and medical device clients to tackle complex challenges. Contact us to learn how our experienced team can help ensure regulatory and development success throughout the product lifecycle.
Interested in gaining an industry edge? Let us help you stay up to date.
Gain an Industry Edge With Expertise From ProPharma Group
Get the latest insights and top tips from our experts, delivered right to your inbox.
Have a complex challenge?